Evidence map›Paper›PMID 35295998›Full record

ArticleFrontiers in oncology2022

Pengyu Yan, Dan Chen, Xutao Yan, Xiaoting Yan, Yingpeng Wang, Chao Liu, Xiaofeng Yang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Frontiers in oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Pengyu YanDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
Dan ChenDepartment of Pathology and Cancer Research Center, Yanbian University Medical College, Yanji, China.
Xutao YanDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
Xiaoting YanDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
Yingpeng WangDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
Chao LiuDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
Xiaofeng YangDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
First Hospital of Shanxi Medical University · CNShanxi Medical University · CNYanbian University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The low detection rate of early and small tumors remains a clinical problem that urgently needs to be solved in the accurate diagnosis and treatment of upper urinary tract urothelial carcinoma (UTUC). The objective of this study is to evaluate the feasibility of CD47 as a target for optical molecular imaging of human UTUC and conduct preliminary Methods: We firstly analyzed the genome-wide mRNA expression data from Gene Expression Omnibus (GEO). Paraffin-embedded tissue specimens comprising UTUC and normal urothelium were collected. All tissue specimens were used for immunohistochemistry to compare CD47 protein expression in normal and cancer tissue. Meanwhile, 12 patients undergoing radical nephroureterectomy were prospectively included in Results: The GEO data revealed that CD47 mRNA expression was higher in UTUC specimens than that in paracancer normal tissue. In immunohistochemical analysis, the CD47 protein expression level was higher in both non-muscle-invasive and muscle-invasive (stage ≥T2) UTUCs than that in normal uroepithelium, and the localization of CD47 protein was the tumor cell membrane. In the Conclusions: CD47-targeted NIR molecular imaging could be a feasible and powerful strategy for the accurate diagnosis of UTUC. Larger-scale randomized trials are needed.

Indexed as

CD47molecular imagingnear-infrared fluorescencetargeted imagingupper urinary tract urothelial carcinoma

Identifiers

PMID35295998
PMCPMC8919026
OpenAlexW4220764714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.